ProtaGene announced a strategic partnership with the Life Science business of Merck, which operates as MilliporeSigma in the United States and Canada, to provide biopharmaceutical customers with an end-to-end testing solution across the entire biopharmaceutical product lifecycle, from early-stage development through GMP release testing.

ProtaGene’s expertise in advanced protein characterization and early-stage drug product characterization is complemented by Merck’s BioReliance® established GMP testing capabilities and global regulatory experience. By connecting these capabilities, the partnership is designed to give customers a comprehensive, high-quality offering tailored to the complex demands of modern biologic drug development.

“This strategic partnership brings together highly complementary capabilities and a shared commitment to scientific excellence,” said Dr. Roland Moussa, President of ProtaGene